source_table,category_or_disease,drug_name,condition_detail,rationale,recommendation,quality,strength
Table 2 (PIM),Antihistamines,Brompheniramine,N/A,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity. Cumulative exposure to anticholinergic drugs is associated with an increased risk of falls, delirium, and dementia, even in younger adults. Consider total anticholinergic burden during regular medication reviews and be cautious in �young-old� as well as �old-old� adults.
Use of diphenhydramine in situations such as acute treatment of severe allergic reactions may be appropriate.",Avoid,Moderate,Strong
Table 2 (PIM),Antihistamines,Chlorpheniramine,N/A,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity. Cumulative exposure to anticholinergic drugs is associated with an increased risk of falls, delirium, and dementia, even in younger adults. Consider total anticholinergic burden during regular medication reviews and be cautious in �young-old� as well as �old-old� adults.
Use of diphenhydramine in situations such as acute treatment of severe allergic reactions may be appropriate.",Avoid,Moderate,Strong
Table 2 (PIM),Antihistamines,Cyproheptadine,N/A,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity. Cumulative exposure to anticholinergic drugs is associated with an increased risk of falls, delirium, and dementia, even in younger adults. Consider total anticholinergic burden during regular medication reviews and be cautious in �young-old� as well as �old-old� adults.
Use of diphenhydramine in situations such as acute treatment of severe allergic reactions may be appropriate.",Avoid,Moderate,Strong
Table 2 (PIM),Antihistamines,Dimenhydrinate,N/A,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity. Cumulative exposure to anticholinergic drugs is associated with an increased risk of falls, delirium, and dementia, even in younger adults. Consider total anticholinergic burden during regular medication reviews and be cautious in �young-old� as well as �old-old� adults.
Use of diphenhydramine in situations such as acute treatment of severe allergic reactions may be appropriate.",Avoid,Moderate,Strong
Table 2 (PIM),Antihistamines,Diphenhydramine,N/A,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity. Cumulative exposure to anticholinergic drugs is associated with an increased risk of falls, delirium, and dementia, even in younger adults. Consider total anticholinergic burden during regular medication reviews and be cautious in �young-old� as well as �old-old� adults.
Use of diphenhydramine in situations such as acute treatment of severe allergic reactions may be appropriate.",Avoid,Moderate,Strong
Table 2 (PIM),Antihistamines,Doxylamine,N/A,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity. Cumulative exposure to anticholinergic drugs is associated with an increased risk of falls, delirium, and dementia, even in younger adults. Consider total anticholinergic burden during regular medication reviews and be cautious in �young-old� as well as �old-old� adults.
Use of diphenhydramine in situations such as acute treatment of severe allergic reactions may be appropriate.",Avoid,Moderate,Strong
Table 2 (PIM),Antihistamines,Hydroxyzine,N/A,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity. Cumulative exposure to anticholinergic drugs is associated with an increased risk of falls, delirium, and dementia, even in younger adults. Consider total anticholinergic burden during regular medication reviews and be cautious in �young-old� as well as �old-old� adults.
Use of diphenhydramine in situations such as acute treatment of severe allergic reactions may be appropriate.",Avoid,Moderate,Strong
Table 2 (PIM),Antihistamines,Meclizine,N/A,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity. Cumulative exposure to anticholinergic drugs is associated with an increased risk of falls, delirium, and dementia, even in younger adults. Consider total anticholinergic burden during regular medication reviews and be cautious in �young-old� as well as �old-old� adults.
Use of diphenhydramine in situations such as acute treatment of severe allergic reactions may be appropriate.",Avoid,Moderate,Strong
Table 2 (PIM),Antihistamines,Promethazine,N/A,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity. Cumulative exposure to anticholinergic drugs is associated with an increased risk of falls, delirium, and dementia, even in younger adults. Consider total anticholinergic burden during regular medication reviews and be cautious in �young-old� as well as �old-old� adults.
Use of diphenhydramine in situations such as acute treatment of severe allergic reactions may be appropriate.",Avoid,Moderate,Strong
Table 2 (PIM),Antihistamines,Triprolidine,N/A,"Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity. Cumulative exposure to anticholinergic drugs is associated with an increased risk of falls, delirium, and dementia, even in younger adults. Consider total anticholinergic burden during regular medication reviews and be cautious in �young-old� as well as �old-old� adults.
Use of diphenhydramine in situations such as acute treatment of severe allergic reactions may be appropriate.",Avoid,Moderate,Strong
Table 2 (PIM),Anti-infective,Nitrofurantoin,N/A,"Potential for pulmonary toxicity, hepatoxicity, and peripheral neuropathy, especially with long-term use; safer alternatives available.",Avoid in individuals with CrCl <30 mL/ min or for long-term suppression.,Low,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Aspirin,primary prevention of cardiovascular disease,"Risk of major bleeding from aspirin increases markedly in older age. Studies suggest a lack of net benefit and potential for net harm when initiated for primary prevention in older adults. There is less evidence about stopping aspirin among long-term users, although similar principles for initiation may apply.
Note: Aspirin is generally indicated for secondary prevention in older adults with established cardiovascular disease.","Avoid initiating aspirin for primary prevention of cardiovascular disease.
Consider deprescribing aspirin in older adults already taking it for primary prevention.",High,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Warfarin,treatment of nonvalvular atrial fibrillation or venous thromboembolism (VTE),"Compared with DOACs, warfarin has higher risks of major bleeding (particularly intracranial bleeding) and similar or lower effectiveness for the treatment of nonvalvular atrial fibrillation and VTE. DOACs are thus the preferred choice for anticoagulation for most people with these conditions.","Avoid starting warfarin as initial therapy for the treatment of nonvalvular atrial fibrillation or VTE unless alternative options (i.e., DOACs) are contraindicated or there are substantial barriers to their use.
For older adults who have been using warfarin long-term, it may be reasonable to continue this medication, particularly among those with well-controlled INRs (i.e., >70% time in the therapeutic range) and no adverse effects.",High,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Rivaroxaban,�long-term treatment of nonvalvular atrial fibrillation or venous thromboembolism (VTE),"At doses used for long-term treatment of VTE or nonvalvular atrial fibrillation, rivaroxaban appears to have a higher risk of major bleeding and GI bleeding in older adults than other DOACs, particularly apixaban.c
Rivaroxaban may be reasonable in special situations, for example when once-daily dosing is necessary to facilitate medication adherence. All DOACs confer a lower risk of intracranial hemorrhage than warfarin.","Avoid for long-term treatment of atrial fibrillation or VTE in favor of safer anticoagulant alternatives.
See also criteria on warfarin (Table 2) and dabigatran (Table 4) and footnote regarding the choice between warfarin and DOACs and among DOACs.",Moderate,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Dipyridamole,oral short-acting (does not apply to extended-release combination with aspirin),May cause orthostatic hypotension; more effective alternatives available; IV form acceptable for use in cardiac stress testing.,Avoid,Moderate,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Doxazosin,Non-selective peripheral alpha-1 blockers for the treatment of hypertension,"High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/benefit profile.",Avoid use as an antihypertensive.,Moderate,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Prazosin,Non-selective peripheral alpha-1 blockers for the treatment of hypertension,"High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/benefit profile.",Avoid use as an antihypertensive.,Moderate,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Terazosin,Non-selective peripheral alpha-1 blockers for the treatment of hypertension,"High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/benefit profile.",Avoid use as an antihypertensive.,Moderate,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Clonidine,Central alpha-agonists for the treatment of hypertension,High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension.,"Avoid clonidine as first-line treatment for hypertension.
Avoid other central alpha-agonists for the treatment of hypertension.",Low,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Guanfacine,Central alpha-agonists for the treatment of hypertension,High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension.,"Avoid clonidine as first-line treatment for hypertension.
Avoid other central alpha-agonists for the treatment of hypertension.",Low,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Nifedipine,immediate release,Potential for hypotension; risk of precipitating myocardial ischemia.,Avoid,High,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Amiodarone,N/A,Effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial fibrillation; may be reasonable first-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control,Avoid as first-line therapy for atrial fibrillation unless the patient has heart failure or substantial left ventricular hypertrophy.,High,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Dronedarone,N/A,"Worse outcomes in people who have permanent atrial fibrillation or severe or recently decompensated heart failure. In some circumstances, worse outcomes have also been reported in people with HFrEF (e.g., left ventricular ejection fraction ?35%) who have milder symptoms (NYHA class I or II).",Avoid in individuals with permanent atrial fibrillation or severe or recently decompensated heart failure. Use caution in patients with HFrEF with less severe symptoms (NYHA class I or II).,High,Strong
Table 2 (PIM),Cardiovascular and antithrombotics,Digoxin,�first-line treatment of atrial fibrillation or heart failure,"Use in atrial fibrillation: should not be used as a first-line agent because there are safer and more effective alternatives for rate control.
Use in heart failure: evidence for benefits and harms of digoxin is conflicting and of lower quality; most (but not all) evidence concerns use in HFrEF. There is strong evidence for other agents as first- line therapy to reduce hospitalizations and mortality in adults with HFrEF. In heart failure, higher dosages are not associated with additional benefits and may increase the risk of toxicity. Use caution in discontinuing digoxin among current users with HFrEF, given limited evidence suggesting worse clinical outcomes after discontinuation.
Decreased renal clearance of digoxin may lead to an increased risk of toxic effects; further dose reduction may be necessary for those with Stage 4 or 5 chronic kidney disease.","Avoid this rate control agent as first-line therapy for atrial fibrillation.Avoid as first-line therapy for heart failure. See rationale for caution about withdrawal in long-term users with HFrEF.If used for atrial fibrillation or heart failure, avoid dosages >0.125 mg/day.","Atrial fibrillation; heart failure: low
Dosage > 0.125 mg/ day: moderate",Strong
Table 2 (PIM),Central nervous system,Amitriptyline,"Antidepressants with strong anticholinergic activity, alone or in combination","Highly anticholinergic, sedating, and cause orthostatic hypotension; the safety profile of low-dose doxepin (?6 mg/day) is comparable to that of placebo.",Avoid,High,Strong
Table 2 (PIM),Central nervous system,Amoxapine,"Antidepressants with strong anticholinergic activity, alone or in combination","Highly anticholinergic, sedating, and cause orthostatic hypotension; the safety profile of low-dose doxepin (?6 mg/day) is comparable to that of placebo.",Avoid,High,Strong
Table 2 (PIM),Central nervous system,Clomipramine,"Antidepressants with strong anticholinergic activity, alone or in combination","Highly anticholinergic, sedating, and cause orthostatic hypotension; the safety profile of low-dose doxepin (?6 mg/day) is comparable to that of placebo.",Avoid,High,Strong
Table 2 (PIM),Central nervous system,Desipramine,"Antidepressants with strong anticholinergic activity, alone or in combination","Highly anticholinergic, sedating, and cause orthostatic hypotension; the safety profile of low-dose doxepin (?6 mg/day) is comparable to that of placebo.",Avoid,High,Strong
Table 2 (PIM),Central nervous system,Doxepin >6 mg/day,"Antidepressants with strong anticholinergic activity, alone or in combination","Highly anticholinergic, sedating, and cause orthostatic hypotension; the safety profile of low-dose doxepin (?6 mg/day) is comparable to that of placebo.",Avoid,High,Strong
Table 2 (PIM),Central nervous system,Imipramine,"Antidepressants with strong anticholinergic activity, alone or in combination","Highly anticholinergic, sedating, and cause orthostatic hypotension; the safety profile of low-dose doxepin (?6 mg/day) is comparable to that of placebo.",Avoid,High,Strong
Table 2 (PIM),Central nervous system,Nortriptyline,"Antidepressants with strong anticholinergic activity, alone or in combination","Highly anticholinergic, sedating, and cause orthostatic hypotension; the safety profile of low-dose doxepin (?6 mg/day) is comparable to that of placebo.",Avoid,High,Strong
Table 2 (PIM),Central nervous system,Paroxetine,"Antidepressants with strong anticholinergic activity, alone or in combination","Highly anticholinergic, sedating, and cause orthostatic hypotension; the safety profile of low-dose doxepin (?6 mg/day) is comparable to that of placebo.",Avoid,High,Strong
Table 2 (PIM),Central nervous system,Benztropine (oral),Antiparkinsonian agents with strong anticholinergic activity,Not recommended for prevention or treatment of extrapyramidal symptoms due to antipsychotics; more effective agents available for the treatment of Parkinson disease.,Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Trihexyphenidyl,Antiparkinsonian agents with strong anticholinergic activity,Not recommended for prevention or treatment of extrapyramidal symptoms due to antipsychotics; more effective agents available for the treatment of Parkinson disease.,Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Aripiprazole,"Antipsychotics, first- (typical) and second- (atypical) generation","Increased risk of stroke and greater rate of cognitive decline and mortality in persons with dementia. Additional evidence suggests an association of increased risk between antipsychotic medication and mortality independent of dementia.Avoid antipsychotics for behavioral problems of dementia or delirium unless documented nonpharmacologic options (e.g., behavioral interventions) have failed and/or the patient is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.","Avoid, except in FDA-approved indications such as schizophrenia, bipolar disorder, Parkinson disease psychosis (see Table 3), adjunctive treatment of major depressive disorder, or for short-term use as an antiemetic.",Moderate,Strong
Table 2 (PIM),Central nervous system,Haloperidol,"Antipsychotics, first- (typical) and second- (atypical) generation","Increased risk of stroke and greater rate of cognitive decline and mortality in persons with dementia. Additional evidence suggests an association of increased risk between antipsychotic medication and mortality independent of dementia.Avoid antipsychotics for behavioral problems of dementia or delirium unless documented nonpharmacologic options (e.g., behavioral interventions) have failed and/or the patient is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.","Avoid, except in FDA-approved indications such as schizophrenia, bipolar disorder, Parkinson disease psychosis (see Table 3), adjunctive treatment of major depressive disorder, or for short-term use as an antiemetic.",Moderate,Strong
Table 2 (PIM),Central nervous system,Olanzapine,"Antipsychotics, first- (typical) and second- (atypical) generation","Increased risk of stroke and greater rate of cognitive decline and mortality in persons with dementia. Additional evidence suggests an association of increased risk between antipsychotic medication and mortality independent of dementia.Avoid antipsychotics for behavioral problems of dementia or delirium unless documented nonpharmacologic options (e.g., behavioral interventions) have failed and/or the patient is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.","Avoid, except in FDA-approved indications such as schizophrenia, bipolar disorder, Parkinson disease psychosis (see Table 3), adjunctive treatment of major depressive disorder, or for short-term use as an antiemetic.",Moderate,Strong
Table 2 (PIM),Central nervous system,Quetiapine,"Antipsychotics, first- (typical) and second- (atypical) generation","Increased risk of stroke and greater rate of cognitive decline and mortality in persons with dementia. Additional evidence suggests an association of increased risk between antipsychotic medication and mortality independent of dementia.Avoid antipsychotics for behavioral problems of dementia or delirium unless documented nonpharmacologic options (e.g., behavioral interventions) have failed and/or the patient is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.","Avoid, except in FDA-approved indications such as schizophrenia, bipolar disorder, Parkinson disease psychosis (see Table 3), adjunctive treatment of major depressive disorder, or for short-term use as an antiemetic.",Moderate,Strong
Table 2 (PIM),Central nervous system,Risperidone,"Antipsychotics, first- (typical) and second- (atypical) generation","Increased risk of stroke and greater rate of cognitive decline and mortality in persons with dementia. Additional evidence suggests an association of increased risk between antipsychotic medication and mortality independent of dementia.Avoid antipsychotics for behavioral problems of dementia or delirium unless documented nonpharmacologic options (e.g., behavioral interventions) have failed and/or the patient is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.","Avoid, except in FDA-approved indications such as schizophrenia, bipolar disorder, Parkinson disease psychosis (see Table 3), adjunctive treatment of major depressive disorder, or for short-term use as an antiemetic.",Moderate,Strong
Table 2 (PIM),Central nervous system,Butalbital,Barbiturates,"High rate of physical dependence, tolerance to sleep benefits, greater risk of overdose at low dosages.",Avoid,High,Strong
Table 2 (PIM),Central nervous system,Phenobarbital,Barbiturates,"High rate of physical dependence, tolerance to sleep benefits, greater risk of overdose at low dosages.",Avoid,High,Strong
Table 2 (PIM),Central nervous system,Primidone,Barbiturates,"High rate of physical dependence, tolerance to sleep benefits, greater risk of overdose at low dosages.",Avoid,High,Strong
Table 2 (PIM),Central nervous system,Alprazolam,Benzodiazepines,"The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction. Concomitant use of opioids may result in profound sedation, respiratory depression, coma, and death.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Chlordiazepoxide,Benzodiazepines,"The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction. Concomitant use of opioids may result in profound sedation, respiratory depression, coma, and death.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Clobazam,Benzodiazepines,"The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction. Concomitant use of opioids may result in profound sedation, respiratory depression, coma, and death.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Clonazepam,Benzodiazepines,"The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction. Concomitant use of opioids may result in profound sedation, respiratory depression, coma, and death.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Clorazepate,Benzodiazepines,"The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction. Concomitant use of opioids may result in profound sedation, respiratory depression, coma, and death.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Diazepam,Benzodiazepines,"The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction. Concomitant use of opioids may result in profound sedation, respiratory depression, coma, and death.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Estazolam,Benzodiazepines,"The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction. Concomitant use of opioids may result in profound sedation, respiratory depression, coma, and death.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Lorazepam,Benzodiazepines,"The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction. Concomitant use of opioids may result in profound sedation, respiratory depression, coma, and death.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Midazolam,Benzodiazepines,"The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction. Concomitant use of opioids may result in profound sedation, respiratory depression, coma, and death.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Oxazepam,Benzodiazepines,"The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction. Concomitant use of opioids may result in profound sedation, respiratory depression, coma, and death.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Temazepam,Benzodiazepines,"The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction. Concomitant use of opioids may result in profound sedation, respiratory depression, coma, and death.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Triazolam,Benzodiazepines,"The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction. Concomitant use of opioids may result in profound sedation, respiratory depression, coma, and death.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents; the continued use of benzodiazepines may lead to clinically significant physical dependence. In general, all benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Eszopiclone,Nonbenzodiazepine benzodiazepine receptor agonist hypnotics,"Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (�Z-drugs�) have adverse events similar to those of benzodiazepines in older adults (e.g., delirium, falls, fractures, increased emergency room visits/ hospitalizations, motor vehicle crashes); minimal improvement in sleep latency and duration.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Zaleplon,Nonbenzodiazepine benzodiazepine receptor agonist hypnotics,"Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (�Z-drugs�) have adverse events similar to those of benzodiazepines in older adults (e.g., delirium, falls, fractures, increased emergency room visits/ hospitalizations, motor vehicle crashes); minimal improvement in sleep latency and duration.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Zolpidem,Nonbenzodiazepine benzodiazepine receptor agonist hypnotics,"Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (�Z-drugs�) have adverse events similar to those of benzodiazepines in older adults (e.g., delirium, falls, fractures, increased emergency room visits/ hospitalizations, motor vehicle crashes); minimal improvement in sleep latency and duration.",Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Meprobamate,N/A,High rate of physical dependence; very sedating.,Avoid,Moderate,Strong
Table 2 (PIM),Central nervous system,Ergoloid mesylates,N/A,Lack of efficacy.,Avoid,High,Strong
Table 2 (PIM),Endocrine,Methyltestosterone,Androgens,Potential for cardiac problems; potential risks in men with prostate cancer.,Avoid unless indicated for confirmed hypogonadism with clinical symptoms.,Moderate,Weak
Table 2 (PIM),Endocrine,Testosterone,Androgens,Potential for cardiac problems; potential risks in men with prostate cancer.,Avoid unless indicated for confirmed hypogonadism with clinical symptoms.,Moderate,Weak
Table 2 (PIM),Endocrine,Insulin,sliding scale (insulin regimens containing only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin),Higher risk of hypoglycemia without improvement in hyperglycemia management regardless of care setting. Avoid insulin regimens that include only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin. This recommendation does not apply to regimens that contain basal insulin or long-acting insulin.,Avoid,Moderate,Strong
Table 2 (PIM),Endocrine,Gliclazide,"Sulfonylureas (all, including short- and longer-acting)","Sulfonylureas have a higher risk of cardiovascular events, all-cause mortality, and hypoglycemia than alternative agents. Sulfonylureas may increase the risk of cardiovascular death and ischemic stroke.
Among sulfonylureas, long-acting agents (e.g., glyburide, glimepiride) confer a higher risk of prolonged hypoglycemia than short-acting agents (e.g., glipizide).","Avoid sulfonylureas as first- or second-line monotherapy or add-on therapy unless there are substantial barriers to the use of safer and more effective agents.
If a sulfonylurea is used, choose short-acting agents (e.g., glipizide) over long- acting agents (e.g., glyburide, glimepiride).","Hypoglycemia: High
CV events and all-cause mortality: Moderate
CV death and ischemic stroke: Low",Strong
Table 2 (PIM),Endocrine,Glimepiride,"Sulfonylureas (all, including short- and longer-acting)","Sulfonylureas have a higher risk of cardiovascular events, all-cause mortality, and hypoglycemia than alternative agents. Sulfonylureas may increase the risk of cardiovascular death and ischemic stroke.
Among sulfonylureas, long-acting agents (e.g., glyburide, glimepiride) confer a higher risk of prolonged hypoglycemia than short-acting agents (e.g., glipizide).","Avoid sulfonylureas as first- or second-line monotherapy or add-on therapy unless there are substantial barriers to the use of safer and more effective agents.
If a sulfonylurea is used, choose short-acting agents (e.g., glipizide) over long- acting agents (e.g., glyburide, glimepiride).","Hypoglycemia: High
CV events and all-cause mortality: Moderate
CV death and ischemic stroke: Low",Strong
Table 2 (PIM),Endocrine,Glipizide,"Sulfonylureas (all, including short- and longer-acting)","Sulfonylureas have a higher risk of cardiovascular events, all-cause mortality, and hypoglycemia than alternative agents. Sulfonylureas may increase the risk of cardiovascular death and ischemic stroke.
Among sulfonylureas, long-acting agents (e.g., glyburide, glimepiride) confer a higher risk of prolonged hypoglycemia than short-acting agents (e.g., glipizide).","Avoid sulfonylureas as first- or second-line monotherapy or add-on therapy unless there are substantial barriers to the use of safer and more effective agents.
If a sulfonylurea is used, choose short-acting agents (e.g., glipizide) over long- acting agents (e.g., glyburide, glimepiride).","Hypoglycemia: High
CV events and all-cause mortality: Moderate
CV death and ischemic stroke: Low",Strong
Table 2 (PIM),Endocrine,Glyburide,"Sulfonylureas (all, including short- and longer-acting)","Sulfonylureas have a higher risk of cardiovascular events, all-cause mortality, and hypoglycemia than alternative agents. Sulfonylureas may increase the risk of cardiovascular death and ischemic stroke.
Among sulfonylureas, long-acting agents (e.g., glyburide, glimepiride) confer a higher risk of prolonged hypoglycemia than short-acting agents (e.g., glipizide).","Avoid sulfonylureas as first- or second-line monotherapy or add-on therapy unless there are substantial barriers to the use of safer and more effective agents.
If a sulfonylurea is used, choose short-acting agents (e.g., glipizide) over long- acting agents (e.g., glyburide, glimepiride).","Hypoglycemia: High
CV events and all-cause mortality: Moderate
CV death and ischemic stroke: Low",Strong
Table 2 (PIM),Endocrine,Glibenclamide,"Sulfonylureas (all, including short- and longer-acting)","Sulfonylureas have a higher risk of cardiovascular events, all-cause mortality, and hypoglycemia than alternative agents. Sulfonylureas may increase the risk of cardiovascular death and ischemic stroke.
Among sulfonylureas, long-acting agents (e.g., glyburide, glimepiride) confer a higher risk of prolonged hypoglycemia than short-acting agents (e.g., glipizide).","Avoid sulfonylureas as first- or second-line monotherapy or add-on therapy unless there are substantial barriers to the use of safer and more effective agents.
If a sulfonylurea is used, choose short-acting agents (e.g., glipizide) over long- acting agents (e.g., glyburide, glimepiride).","Hypoglycemia: High
CV events and all-cause mortality: Moderate
CV death and ischemic stroke: Low",Strong
Table 2 (PIM),Endocrine,Desiccated thyroid,N/A,Concerns about cardiac effects; safer alternatives available.,Avoid,Low,Strong
Table 2 (PIM),Endocrine,Megestrol,N/A,Minimal effect on weight; increases the risk of thrombotic events and possibly death in older adults.,Avoid,Moderate,Strong
Table 2 (PIM),Endocrine,Growth hormone,N/A,"Impact on body composition is small and associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, and impaired fasting glucose.","Avoid, except for patients rigorously diagnosed by evidence-based criteria with growth hormone deficiency due to an established etiology.",High,Strong
Table 2 (PIM),Gastrointestinal,Dexlansoprazole,Proton-pump inhibitors,"Risk of�C. difficile�infection, pneumonia, GI malignancies, bone loss, and fractures.","Avoid scheduled use for >8 weeks unless for high-risk patients (e.g., oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett�s esophagitis, pathologic hypersecretory condition, or demonstrated need for maintenance treatment (e.g., because of failure of drug discontinuation trial or H2-receptor antagonists).","C. difficile, bone loss, and fractures: High
Pneumonia and GI malignancies: Moderate",Strong
Table 2 (PIM),Gastrointestinal,Esomeprazole,Proton-pump inhibitors,"Risk of�C. difficile�infection, pneumonia, GI malignancies, bone loss, and fractures.","Avoid scheduled use for >8 weeks unless for high-risk patients (e.g., oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett�s esophagitis, pathologic hypersecretory condition, or demonstrated need for maintenance treatment (e.g., because of failure of drug discontinuation trial or H2-receptor antagonists).","C. difficile, bone loss, and fractures: High
Pneumonia and GI malignancies: Moderate",Strong
Table 2 (PIM),Gastrointestinal,Lansoprazole,Proton-pump inhibitors,"Risk of�C. difficile�infection, pneumonia, GI malignancies, bone loss, and fractures.","Avoid scheduled use for >8 weeks unless for high-risk patients (e.g., oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett�s esophagitis, pathologic hypersecretory condition, or demonstrated need for maintenance treatment (e.g., because of failure of drug discontinuation trial or H2-receptor antagonists).","C. difficile, bone loss, and fractures: High
Pneumonia and GI malignancies: Moderate",Strong
Table 2 (PIM),Gastrointestinal,Omeprazole,Proton-pump inhibitors,"Risk of�C. difficile�infection, pneumonia, GI malignancies, bone loss, and fractures.","Avoid scheduled use for >8 weeks unless for high-risk patients (e.g., oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett�s esophagitis, pathologic hypersecretory condition, or demonstrated need for maintenance treatment (e.g., because of failure of drug discontinuation trial or H2-receptor antagonists).","C. difficile, bone loss, and fractures: High
Pneumonia and GI malignancies: Moderate",Strong
Table 2 (PIM),Gastrointestinal,Pantoprazole,Proton-pump inhibitors,"Risk of�C. difficile�infection, pneumonia, GI malignancies, bone loss, and fractures.","Avoid scheduled use for >8 weeks unless for high-risk patients (e.g., oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett�s esophagitis, pathologic hypersecretory condition, or demonstrated need for maintenance treatment (e.g., because of failure of drug discontinuation trial or H2-receptor antagonists).","C. difficile, bone loss, and fractures: High
Pneumonia and GI malignancies: Moderate",Strong
Table 2 (PIM),Gastrointestinal,Rabeprazole,Proton-pump inhibitors,"Risk of�C. difficile�infection, pneumonia, GI malignancies, bone loss, and fractures.","Avoid scheduled use for >8 weeks unless for high-risk patients (e.g., oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett�s esophagitis, pathologic hypersecretory condition, or demonstrated need for maintenance treatment (e.g., because of failure of drug discontinuation trial or H2-receptor antagonists).","C. difficile, bone loss, and fractures: High
Pneumonia and GI malignancies: Moderate",Strong
Table 2 (PIM),Gastrointestinal,Metoclopramide,N/A,"Can cause extrapyramidal effects, including tardive dyskinesia; the risk may be greater in frail older adults and with prolonged exposure.","Avoid, unless for gastroparesis with a duration of use not to exceed 12 weeks except in rare cases.",Moderate,Strong
Table 2 (PIM),Gastrointestinal,Hyoscyamine,GI antispasmodics with strong anticholinergic activity Atropine (excludes ophthalmic) Clidinium-chlordiazepoxide Dicyclomine,"Highly anticholinergic, uncertain effectiveness.",Avoid,Moderate,Strong
Table 2 (PIM),Gastrointestinal,Scopolamine,GI antispasmodics with strong anticholinergic activity Atropine (excludes ophthalmic) Clidinium-chlordiazepoxide Dicyclomine,"Highly anticholinergic, uncertain effectiveness.",Avoid,Moderate,Strong
Table 2 (PIM),Genitourinary,Desmopressin,N/A,High risk of hyponatremia; safer alternative treatments for nocturia (including non- pharmacologic).,Avoid for treatment of nocturia or nocturnal polyuria.,Moderate,Strong
Table 2 (PIM),Pain medications,Aspirin >325 mg/day,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Diclofenac,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Diflunisal,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Etodolac,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Flurbiprofen,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Ibuprofen,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Indomethacin,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Ketorolac,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Meloxicam,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Nabumetone,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Naproxen,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Oxaprozin,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Piroxicam,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Sulindac,"Non-COX-2-selective NSAIDs, oral:","Increased risk of GI bleeding or peptic ulcer disease in high-risk groups, including those >75 years old or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for 3�6 months and in ~2%?4% of patients treated for 1 year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. Risks are dose-related.","Avoid chronic use unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).
Avoid short-term scheduled use in combination with oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents unless other alternatives are not effective and the patient can take a gastroprotective agent (proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 2 (PIM),Pain medications,Indomethacin,N/A,"Increased risk of GI bleeding/peptic ulcer disease and acute kidney injury in older adults. Of all the NSAIDs, indomethacin has the most adverse effects, including a higher risk of adverse CNS effects.",Avoid,Moderate,Strong
Table 2 (PIM),Pain medications,Ketorolac,N/A,"Increased risk of GI bleeding/peptic ulcer disease and acute kidney injury in older adults. Of all the NSAIDs, indomethacin has the most adverse effects, including a higher risk of adverse CNS effects.",Avoid,Moderate,Strong
Table 2 (PIM),Pain medications,Meperidine,N/A,"Oral analgesic not effective in dosages commonly used; may have a higher risk of neurotoxicity, including delirium, than other opioids; safer alternatives available.",Avoid,Moderate,Strong
Table 2 (PIM),Pain medications,Carisoprodol,Skeletal muscle relaxants,"Muscle relaxants typically used to treat musculoskeletal complaints are poorly tolerated by older adults due to anticholinergic adverse effects, sedation, and increased risk of fractures; effectiveness at dosages tolerated by older adults is questionable.
This criterion does not apply to skeletal muscle relaxants typically used for the management of spasticity (i.e., baclofen and tizanidine) although these drugs can also cause substantial adverse effects.",Avoid,Moderate,Strong
Table 2 (PIM),Pain medications,Chlorzoxazone,Skeletal muscle relaxants,"Muscle relaxants typically used to treat musculoskeletal complaints are poorly tolerated by older adults due to anticholinergic adverse effects, sedation, and increased risk of fractures; effectiveness at dosages tolerated by older adults is questionable.
This criterion does not apply to skeletal muscle relaxants typically used for the management of spasticity (i.e., baclofen and tizanidine) although these drugs can also cause substantial adverse effects.",Avoid,Moderate,Strong
Table 2 (PIM),Pain medications,Cyclobenzaprine,Skeletal muscle relaxants,"Muscle relaxants typically used to treat musculoskeletal complaints are poorly tolerated by older adults due to anticholinergic adverse effects, sedation, and increased risk of fractures; effectiveness at dosages tolerated by older adults is questionable.
This criterion does not apply to skeletal muscle relaxants typically used for the management of spasticity (i.e., baclofen and tizanidine) although these drugs can also cause substantial adverse effects.",Avoid,Moderate,Strong
Table 2 (PIM),Pain medications,Metaxalone,Skeletal muscle relaxants,"Muscle relaxants typically used to treat musculoskeletal complaints are poorly tolerated by older adults due to anticholinergic adverse effects, sedation, and increased risk of fractures; effectiveness at dosages tolerated by older adults is questionable.
This criterion does not apply to skeletal muscle relaxants typically used for the management of spasticity (i.e., baclofen and tizanidine) although these drugs can also cause substantial adverse effects.",Avoid,Moderate,Strong
Table 2 (PIM),Pain medications,Methocarbamol,Skeletal muscle relaxants,"Muscle relaxants typically used to treat musculoskeletal complaints are poorly tolerated by older adults due to anticholinergic adverse effects, sedation, and increased risk of fractures; effectiveness at dosages tolerated by older adults is questionable.
This criterion does not apply to skeletal muscle relaxants typically used for the management of spasticity (i.e., baclofen and tizanidine) although these drugs can also cause substantial adverse effects.",Avoid,Moderate,Strong
Table 2 (PIM),Pain medications,Orphenadrine,Skeletal muscle relaxants,"Muscle relaxants typically used to treat musculoskeletal complaints are poorly tolerated by older adults due to anticholinergic adverse effects, sedation, and increased risk of fractures; effectiveness at dosages tolerated by older adults is questionable.
This criterion does not apply to skeletal muscle relaxants typically used for the management of spasticity (i.e., baclofen and tizanidine) although these drugs can also cause substantial adverse effects.",Avoid,Moderate,Strong
Table 3 (Disease),Cardiovascular,Cilostazol,Heart failure,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, non-dihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone); concerns about QT prolongation (dextromethorphan-quinidine).
Note: This is not a comprehensive list of medications to avoid in patients with heart failure.","Avoid:
Cilostazol
Dextromethorphan-quinidine
-----------------
Avoid in heart failure with reduced ejection fraction:
Nondihydropyridine calcium channel blockers (CCBs) Diltiazem
Verapamil
---------------
Use with caution in patients with heart failure who are asymptomatic; avoid in patients with symptomatic heart failure:
Dronedarone
NSAIDs and COX-2 inhibitors
Thiazolidinediones
Pioglitazone","Cilostazol, dextromethorphanquinidine, COX-2 inhibitors: Low
Non-dihydropyridine CCBs, NSAIDs: Moderate
Dronedarone, thiazolidenediones: High",Strong
Table 3 (Disease),Cardiovascular,Dextromethorphan-quinidine,Heart failure,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, non-dihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone); concerns about QT prolongation (dextromethorphan-quinidine).
Note: This is not a comprehensive list of medications to avoid in patients with heart failure.","Avoid:
Cilostazol
Dextromethorphan-quinidine
-----------------
Avoid in heart failure with reduced ejection fraction:
Nondihydropyridine calcium channel blockers (CCBs) Diltiazem
Verapamil
---------------
Use with caution in patients with heart failure who are asymptomatic; avoid in patients with symptomatic heart failure:
Dronedarone
NSAIDs and COX-2 inhibitors
Thiazolidinediones
Pioglitazone","Cilostazol, dextromethorphanquinidine, COX-2 inhibitors: Low
Non-dihydropyridine CCBs, NSAIDs: Moderate
Dronedarone, thiazolidenediones: High",Strong
Table 3 (Disease),Cardiovascular,Nondihydropyridine calcium,Heart failure,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, non-dihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone); concerns about QT prolongation (dextromethorphan-quinidine).
Note: This is not a comprehensive list of medications to avoid in patients with heart failure.","Avoid:
Cilostazol
Dextromethorphan-quinidine
-----------------
Avoid in heart failure with reduced ejection fraction:
Nondihydropyridine calcium channel blockers (CCBs) Diltiazem
Verapamil
---------------
Use with caution in patients with heart failure who are asymptomatic; avoid in patients with symptomatic heart failure:
Dronedarone
NSAIDs and COX-2 inhibitors
Thiazolidinediones
Pioglitazone","Cilostazol, dextromethorphanquinidine, COX-2 inhibitors: Low
Non-dihydropyridine CCBs, NSAIDs: Moderate
Dronedarone, thiazolidenediones: High",Strong
Table 3 (Disease),Cardiovascular,Diltiazem,Heart failure,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, non-dihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone); concerns about QT prolongation (dextromethorphan-quinidine).
Note: This is not a comprehensive list of medications to avoid in patients with heart failure.","Avoid:
Cilostazol
Dextromethorphan-quinidine
-----------------
Avoid in heart failure with reduced ejection fraction:
Nondihydropyridine calcium channel blockers (CCBs) Diltiazem
Verapamil
---------------
Use with caution in patients with heart failure who are asymptomatic; avoid in patients with symptomatic heart failure:
Dronedarone
NSAIDs and COX-2 inhibitors
Thiazolidinediones
Pioglitazone","Cilostazol, dextromethorphanquinidine, COX-2 inhibitors: Low
Non-dihydropyridine CCBs, NSAIDs: Moderate
Dronedarone, thiazolidenediones: High",Strong
Table 3 (Disease),Cardiovascular,Verapamil,Heart failure,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, non-dihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone); concerns about QT prolongation (dextromethorphan-quinidine).
Note: This is not a comprehensive list of medications to avoid in patients with heart failure.","Avoid:
Cilostazol
Dextromethorphan-quinidine
-----------------
Avoid in heart failure with reduced ejection fraction:
Nondihydropyridine calcium channel blockers (CCBs) Diltiazem
Verapamil
---------------
Use with caution in patients with heart failure who are asymptomatic; avoid in patients with symptomatic heart failure:
Dronedarone
NSAIDs and COX-2 inhibitors
Thiazolidinediones
Pioglitazone","Cilostazol, dextromethorphanquinidine, COX-2 inhibitors: Low
Non-dihydropyridine CCBs, NSAIDs: Moderate
Dronedarone, thiazolidenediones: High",Strong
Table 3 (Disease),Cardiovascular,Dronedarone,Heart failure,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, non-dihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone); concerns about QT prolongation (dextromethorphan-quinidine).
Note: This is not a comprehensive list of medications to avoid in patients with heart failure.","Avoid:
Cilostazol
Dextromethorphan-quinidine
-----------------
Avoid in heart failure with reduced ejection fraction:
Nondihydropyridine calcium channel blockers (CCBs) Diltiazem
Verapamil
---------------
Use with caution in patients with heart failure who are asymptomatic; avoid in patients with symptomatic heart failure:
Dronedarone
NSAIDs and COX-2 inhibitors
Thiazolidinediones
Pioglitazone","Cilostazol, dextromethorphanquinidine, COX-2 inhibitors: Low
Non-dihydropyridine CCBs, NSAIDs: Moderate
Dronedarone, thiazolidenediones: High",Strong
Table 3 (Disease),Cardiovascular,NSAIDs and COX-2 inhibitors,Heart failure,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, non-dihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone); concerns about QT prolongation (dextromethorphan-quinidine).
Note: This is not a comprehensive list of medications to avoid in patients with heart failure.","Avoid:
Cilostazol
Dextromethorphan-quinidine
-----------------
Avoid in heart failure with reduced ejection fraction:
Nondihydropyridine calcium channel blockers (CCBs) Diltiazem
Verapamil
---------------
Use with caution in patients with heart failure who are asymptomatic; avoid in patients with symptomatic heart failure:
Dronedarone
NSAIDs and COX-2 inhibitors
Thiazolidinediones
Pioglitazone","Cilostazol, dextromethorphanquinidine, COX-2 inhibitors: Low
Non-dihydropyridine CCBs, NSAIDs: Moderate
Dronedarone, thiazolidenediones: High",Strong
Table 3 (Disease),Cardiovascular,Thiazolidinediones,Heart failure,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, non-dihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone); concerns about QT prolongation (dextromethorphan-quinidine).
Note: This is not a comprehensive list of medications to avoid in patients with heart failure.","Avoid:
Cilostazol
Dextromethorphan-quinidine
-----------------
Avoid in heart failure with reduced ejection fraction:
Nondihydropyridine calcium channel blockers (CCBs) Diltiazem
Verapamil
---------------
Use with caution in patients with heart failure who are asymptomatic; avoid in patients with symptomatic heart failure:
Dronedarone
NSAIDs and COX-2 inhibitors
Thiazolidinediones
Pioglitazone","Cilostazol, dextromethorphanquinidine, COX-2 inhibitors: Low
Non-dihydropyridine CCBs, NSAIDs: Moderate
Dronedarone, thiazolidenediones: High",Strong
Table 3 (Disease),Cardiovascular,Pioglitazone,Heart failure,"Potential to promote fluid retention and/or exacerbate heart failure (NSAIDs and COX-2 inhibitors, non-dihydropyridine CCBs, thiazolidinediones); potential to increase mortality in older adults with heart failure (cilostazol and dronedarone); concerns about QT prolongation (dextromethorphan-quinidine).
Note: This is not a comprehensive list of medications to avoid in patients with heart failure.","Avoid:
Cilostazol
Dextromethorphan-quinidine
-----------------
Avoid in heart failure with reduced ejection fraction:
Nondihydropyridine calcium channel blockers (CCBs) Diltiazem
Verapamil
---------------
Use with caution in patients with heart failure who are asymptomatic; avoid in patients with symptomatic heart failure:
Dronedarone
NSAIDs and COX-2 inhibitors
Thiazolidinediones
Pioglitazone","Cilostazol, dextromethorphanquinidine, COX-2 inhibitors: Low
Non-dihydropyridine CCBs, NSAIDs: Moderate
Dronedarone, thiazolidenediones: High",Strong
Table 3 (Disease),Cardiovascular,Chlorpromazine,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Cardiovascular,Olanzapine,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Cardiovascular,Donepezil,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Cardiovascular,Galantamine,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Cardiovascular,Rivastigmine,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Cardiovascular,blockers,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Cardiovascular,Doxazosin,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Cardiovascular,Prazosin,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Cardiovascular,Terazosin,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Cardiovascular,Amitriptyline,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Cardiovascular,Clomipramine,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Cardiovascular,Doxepin,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Cardiovascular,Imipramine,Syncope,"Antipsychotics listed and tertiary TCAs increase the risk of orthostatic hypotension.
AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia.
Non-selective peripheral alpha-1 blockers cause orthostatic blood pressure changes and should be avoided in older adults whose syncope may be due to orthostatic hypotension.",Avoid,High,"Antipsychotics, non-selective peripheral alpha-1 blockers: Weak
AChEIs, tertiary TCAs: Strong"
Table 3 (Disease),Central nervous system,Anticholinergics,Delirium,"Avoid in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium.
Antipsychotics: avoid for behavioral problems of dementia or delirium unless nonpharmacologic options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.
Corticosteroids: if needed, use the lowest possible dose for the shortest duration and monitor for delirium.
Opioids: emerging data highlights an association between opioid administration and delirium. For older adults with pain, use a balanced approach, including the use of validated pain assessment tools and multimodal strategies that include nondrug approaches to minimize opioid use.","Avoid, except in situations listed under the rationale statement.","H2-receptor antagonists: Low
All others: Moderate",Strong
Table 3 (Disease),Central nervous system,Antipsychotics,Delirium,"Avoid in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium.
Antipsychotics: avoid for behavioral problems of dementia or delirium unless nonpharmacologic options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.
Corticosteroids: if needed, use the lowest possible dose for the shortest duration and monitor for delirium.
Opioids: emerging data highlights an association between opioid administration and delirium. For older adults with pain, use a balanced approach, including the use of validated pain assessment tools and multimodal strategies that include nondrug approaches to minimize opioid use.","Avoid, except in situations listed under the rationale statement.","H2-receptor antagonists: Low
All others: Moderate",Strong
Table 3 (Disease),Central nervous system,Benzodiazepines,Delirium,"Avoid in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium.
Antipsychotics: avoid for behavioral problems of dementia or delirium unless nonpharmacologic options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.
Corticosteroids: if needed, use the lowest possible dose for the shortest duration and monitor for delirium.
Opioids: emerging data highlights an association between opioid administration and delirium. For older adults with pain, use a balanced approach, including the use of validated pain assessment tools and multimodal strategies that include nondrug approaches to minimize opioid use.","Avoid, except in situations listed under the rationale statement.","H2-receptor antagonists: Low
All others: Moderate",Strong
Table 3 (Disease),Central nervous system,Corticosteroids,Delirium,"Avoid in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium.
Antipsychotics: avoid for behavioral problems of dementia or delirium unless nonpharmacologic options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.
Corticosteroids: if needed, use the lowest possible dose for the shortest duration and monitor for delirium.
Opioids: emerging data highlights an association between opioid administration and delirium. For older adults with pain, use a balanced approach, including the use of validated pain assessment tools and multimodal strategies that include nondrug approaches to minimize opioid use.","Avoid, except in situations listed under the rationale statement.","H2-receptor antagonists: Low
All others: Moderate",Strong
Table 3 (Disease),Central nervous system,Cimetidine,Delirium,"Avoid in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium.
Antipsychotics: avoid for behavioral problems of dementia or delirium unless nonpharmacologic options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.
Corticosteroids: if needed, use the lowest possible dose for the shortest duration and monitor for delirium.
Opioids: emerging data highlights an association between opioid administration and delirium. For older adults with pain, use a balanced approach, including the use of validated pain assessment tools and multimodal strategies that include nondrug approaches to minimize opioid use.","Avoid, except in situations listed under the rationale statement.","H2-receptor antagonists: Low
All others: Moderate",Strong
Table 3 (Disease),Central nervous system,Famotidine,Delirium,"Avoid in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium.
Antipsychotics: avoid for behavioral problems of dementia or delirium unless nonpharmacologic options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.
Corticosteroids: if needed, use the lowest possible dose for the shortest duration and monitor for delirium.
Opioids: emerging data highlights an association between opioid administration and delirium. For older adults with pain, use a balanced approach, including the use of validated pain assessment tools and multimodal strategies that include nondrug approaches to minimize opioid use.","Avoid, except in situations listed under the rationale statement.","H2-receptor antagonists: Low
All others: Moderate",Strong
Table 3 (Disease),Central nervous system,Nizatidine,Delirium,"Avoid in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium.
Antipsychotics: avoid for behavioral problems of dementia or delirium unless nonpharmacologic options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.
Corticosteroids: if needed, use the lowest possible dose for the shortest duration and monitor for delirium.
Opioids: emerging data highlights an association between opioid administration and delirium. For older adults with pain, use a balanced approach, including the use of validated pain assessment tools and multimodal strategies that include nondrug approaches to minimize opioid use.","Avoid, except in situations listed under the rationale statement.","H2-receptor antagonists: Low
All others: Moderate",Strong
Table 3 (Disease),Central nervous system,Nonbenzodiazepine,Delirium,"Avoid in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium.
Antipsychotics: avoid for behavioral problems of dementia or delirium unless nonpharmacologic options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.
Corticosteroids: if needed, use the lowest possible dose for the shortest duration and monitor for delirium.
Opioids: emerging data highlights an association between opioid administration and delirium. For older adults with pain, use a balanced approach, including the use of validated pain assessment tools and multimodal strategies that include nondrug approaches to minimize opioid use.","Avoid, except in situations listed under the rationale statement.","H2-receptor antagonists: Low
All others: Moderate",Strong
Table 3 (Disease),Central nervous system,Eszopiclone,Delirium,"Avoid in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium.
Antipsychotics: avoid for behavioral problems of dementia or delirium unless nonpharmacologic options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.
Corticosteroids: if needed, use the lowest possible dose for the shortest duration and monitor for delirium.
Opioids: emerging data highlights an association between opioid administration and delirium. For older adults with pain, use a balanced approach, including the use of validated pain assessment tools and multimodal strategies that include nondrug approaches to minimize opioid use.","Avoid, except in situations listed under the rationale statement.","H2-receptor antagonists: Low
All others: Moderate",Strong
Table 3 (Disease),Central nervous system,Zaleplon,Delirium,"Avoid in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium.
Antipsychotics: avoid for behavioral problems of dementia or delirium unless nonpharmacologic options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.
Corticosteroids: if needed, use the lowest possible dose for the shortest duration and monitor for delirium.
Opioids: emerging data highlights an association between opioid administration and delirium. For older adults with pain, use a balanced approach, including the use of validated pain assessment tools and multimodal strategies that include nondrug approaches to minimize opioid use.","Avoid, except in situations listed under the rationale statement.","H2-receptor antagonists: Low
All others: Moderate",Strong
Table 3 (Disease),Central nervous system,Zolpidem,Delirium,"Avoid in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium.
Antipsychotics: avoid for behavioral problems of dementia or delirium unless nonpharmacologic options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.
Corticosteroids: if needed, use the lowest possible dose for the shortest duration and monitor for delirium.
Opioids: emerging data highlights an association between opioid administration and delirium. For older adults with pain, use a balanced approach, including the use of validated pain assessment tools and multimodal strategies that include nondrug approaches to minimize opioid use.","Avoid, except in situations listed under the rationale statement.","H2-receptor antagonists: Low
All others: Moderate",Strong
Table 3 (Disease),Central nervous system,Opioids,Delirium,"Avoid in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium.
Antipsychotics: avoid for behavioral problems of dementia or delirium unless nonpharmacologic options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.
Corticosteroids: if needed, use the lowest possible dose for the shortest duration and monitor for delirium.
Opioids: emerging data highlights an association between opioid administration and delirium. For older adults with pain, use a balanced approach, including the use of validated pain assessment tools and multimodal strategies that include nondrug approaches to minimize opioid use.","Avoid, except in situations listed under the rationale statement.","H2-receptor antagonists: Low
All others: Moderate",Strong
Table 3 (Disease),Central nervous system,Antipsychotics,Dementia or cognitive impairment,"Avoid because of adverse CNS effects. See criteria on individual drugs for additional information.
Antipsychotics: increased risk of stroke and greater rate of cognitive decline and mortality in people with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless documented nonpharmacologic options (e.g., behavioral interventions) have failed and/or the patient is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.",Avoid,Moderate,Strong
Table 3 (Disease),Central nervous system,Benzodiazepines,Dementia or cognitive impairment,"Avoid because of adverse CNS effects. See criteria on individual drugs for additional information.
Antipsychotics: increased risk of stroke and greater rate of cognitive decline and mortality in people with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless documented nonpharmacologic options (e.g., behavioral interventions) have failed and/or the patient is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.",Avoid,Moderate,Strong
Table 3 (Disease),Central nervous system,Nonbenzodiazepine,Dementia or cognitive impairment,"Avoid because of adverse CNS effects. See criteria on individual drugs for additional information.
Antipsychotics: increased risk of stroke and greater rate of cognitive decline and mortality in people with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless documented nonpharmacologic options (e.g., behavioral interventions) have failed and/or the patient is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.",Avoid,Moderate,Strong
Table 3 (Disease),Central nervous system,Eszopiclone,Dementia or cognitive impairment,"Avoid because of adverse CNS effects. See criteria on individual drugs for additional information.
Antipsychotics: increased risk of stroke and greater rate of cognitive decline and mortality in people with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless documented nonpharmacologic options (e.g., behavioral interventions) have failed and/or the patient is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.",Avoid,Moderate,Strong
Table 3 (Disease),Central nervous system,Zaleplon,Dementia or cognitive impairment,"Avoid because of adverse CNS effects. See criteria on individual drugs for additional information.
Antipsychotics: increased risk of stroke and greater rate of cognitive decline and mortality in people with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless documented nonpharmacologic options (e.g., behavioral interventions) have failed and/or the patient is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.",Avoid,Moderate,Strong
Table 3 (Disease),Central nervous system,Zolpidem,Dementia or cognitive impairment,"Avoid because of adverse CNS effects. See criteria on individual drugs for additional information.
Antipsychotics: increased risk of stroke and greater rate of cognitive decline and mortality in people with dementia. Avoid antipsychotics for behavioral problems of dementia or delirium unless documented nonpharmacologic options (e.g., behavioral interventions) have failed and/or the patient is threatening substantial harm to self or others. If used, periodic deprescribing attempts should be considered to assess ongoing need and/or the lowest effective dose.",Avoid,Moderate,Strong
Table 3 (Disease),Central nervous system,SNRIs,History of falls or fractures,"May cause ataxia, impaired psychomotor function, syncope, or additional falls.
Antidepressants (selected classes): evidence for risk of falls and fractures is mixed; newer evidence suggests that SNRIs may increase falls risk.
Benzodiazepines: shorter-acting ones are not safer than long-acting ones.
If one of the drugs must be used, consider reducing the use of other CNS-active medications that increase the risk of falls and fractures","Avoid unless safer alternatives are not available.
Antiepileptics: avoid except for seizures and mood disorders.
Opioids: avoid except for pain management in the setting of severe acute pain.","Antidepressants, opioids: Moderate
All others: High",Strong
Table 3 (Disease),Central nervous system,SSRIs,History of falls or fractures,"May cause ataxia, impaired psychomotor function, syncope, or additional falls.
Antidepressants (selected classes): evidence for risk of falls and fractures is mixed; newer evidence suggests that SNRIs may increase falls risk.
Benzodiazepines: shorter-acting ones are not safer than long-acting ones.
If one of the drugs must be used, consider reducing the use of other CNS-active medications that increase the risk of falls and fractures","Avoid unless safer alternatives are not available.
Antiepileptics: avoid except for seizures and mood disorders.
Opioids: avoid except for pain management in the setting of severe acute pain.","Antidepressants, opioids: Moderate
All others: High",Strong
Table 3 (Disease),Central nervous system,Tricyclic antidepressants (TCAs),History of falls or fractures,"May cause ataxia, impaired psychomotor function, syncope, or additional falls.
Antidepressants (selected classes): evidence for risk of falls and fractures is mixed; newer evidence suggests that SNRIs may increase falls risk.
Benzodiazepines: shorter-acting ones are not safer than long-acting ones.
If one of the drugs must be used, consider reducing the use of other CNS-active medications that increase the risk of falls and fractures","Avoid unless safer alternatives are not available.
Antiepileptics: avoid except for seizures and mood disorders.
Opioids: avoid except for pain management in the setting of severe acute pain.","Antidepressants, opioids: Moderate
All others: High",Strong
Table 3 (Disease),Central nervous system,Antiepileptics,History of falls or fractures,"May cause ataxia, impaired psychomotor function, syncope, or additional falls.
Antidepressants (selected classes): evidence for risk of falls and fractures is mixed; newer evidence suggests that SNRIs may increase falls risk.
Benzodiazepines: shorter-acting ones are not safer than long-acting ones.
If one of the drugs must be used, consider reducing the use of other CNS-active medications that increase the risk of falls and fractures","Avoid unless safer alternatives are not available.
Antiepileptics: avoid except for seizures and mood disorders.
Opioids: avoid except for pain management in the setting of severe acute pain.","Antidepressants, opioids: Moderate
All others: High",Strong
Table 3 (Disease),Central nervous system,Antipsychotics,History of falls or fractures,"May cause ataxia, impaired psychomotor function, syncope, or additional falls.
Antidepressants (selected classes): evidence for risk of falls and fractures is mixed; newer evidence suggests that SNRIs may increase falls risk.
Benzodiazepines: shorter-acting ones are not safer than long-acting ones.
If one of the drugs must be used, consider reducing the use of other CNS-active medications that increase the risk of falls and fractures","Avoid unless safer alternatives are not available.
Antiepileptics: avoid except for seizures and mood disorders.
Opioids: avoid except for pain management in the setting of severe acute pain.","Antidepressants, opioids: Moderate
All others: High",Strong
Table 3 (Disease),Central nervous system,Benzodiazepines,History of falls or fractures,"May cause ataxia, impaired psychomotor function, syncope, or additional falls.
Antidepressants (selected classes): evidence for risk of falls and fractures is mixed; newer evidence suggests that SNRIs may increase falls risk.
Benzodiazepines: shorter-acting ones are not safer than long-acting ones.
If one of the drugs must be used, consider reducing the use of other CNS-active medications that increase the risk of falls and fractures","Avoid unless safer alternatives are not available.
Antiepileptics: avoid except for seizures and mood disorders.
Opioids: avoid except for pain management in the setting of severe acute pain.","Antidepressants, opioids: Moderate
All others: High",Strong
Table 3 (Disease),Central nervous system,Antiemetics,Parkinson disease,"Dopamine-receptor antagonists with the potential to worsen parkinsonian symptoms
Exceptions: clozapine, pimavanserin, and quetiapine appear to be less likely to precipitate the worsening of Parkinson disease than other antipsychotics.",Avoid,Moderate,Strong
Table 3 (Disease),Central nervous system,Metoclopramide,Parkinson disease,"Dopamine-receptor antagonists with the potential to worsen parkinsonian symptoms
Exceptions: clozapine, pimavanserin, and quetiapine appear to be less likely to precipitate the worsening of Parkinson disease than other antipsychotics.",Avoid,Moderate,Strong
Table 3 (Disease),Central nervous system,Prochlorperazine,Parkinson disease,"Dopamine-receptor antagonists with the potential to worsen parkinsonian symptoms
Exceptions: clozapine, pimavanserin, and quetiapine appear to be less likely to precipitate the worsening of Parkinson disease than other antipsychotics.",Avoid,Moderate,Strong
Table 3 (Disease),Central nervous system,Promethazine,Parkinson disease,"Dopamine-receptor antagonists with the potential to worsen parkinsonian symptoms
Exceptions: clozapine, pimavanserin, and quetiapine appear to be less likely to precipitate the worsening of Parkinson disease than other antipsychotics.",Avoid,Moderate,Strong
Table 3 (Disease),Central nervous system,Antipsychotics,Parkinson disease,"Dopamine-receptor antagonists with the potential to worsen parkinsonian symptoms
Exceptions: clozapine, pimavanserin, and quetiapine appear to be less likely to precipitate the worsening of Parkinson disease than other antipsychotics.",Avoid,Moderate,Strong
Table 3 (Disease),Gastrointestinal,Aspirin,History of gastric or duodenal ulcers,May exacerbate existing ulcers or cause new/additional ulcers,"Avoid unless other alternatives are not effective and the patient can take a gastroprotective agent (i.e., proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 3 (Disease),Gastrointestinal,Non-COX-2 selective NSAIDs,History of gastric or duodenal ulcers,May exacerbate existing ulcers or cause new/additional ulcers,"Avoid unless other alternatives are not effective and the patient can take a gastroprotective agent (i.e., proton-pump inhibitor or misoprostol).",Moderate,Strong
Table 3 (Disease),Kidney/urinary tract,Doxazosin,Urinary incontinence (all types) in women,"Aggravation of incontinence (alpha-1 blockers), lack of efficacy (oral estrogen)",Avoid in women,"Non-selective peripheral alpha-1 blockers: Moderate
Estrogen: High","Non-selective peripheral alpha-1 blockers: Strong
Estrogen: Strong"
Table 3 (Disease),Kidney/urinary tract,Prazosin,Urinary incontinence (all types) in women,"Aggravation of incontinence (alpha-1 blockers), lack of efficacy (oral estrogen)",Avoid in women,"Non-selective peripheral alpha-1 blockers: Moderate
Estrogen: High","Non-selective peripheral alpha-1 blockers: Strong
Estrogen: Strong"
Table 3 (Disease),Kidney/urinary tract,Terazosin,Urinary incontinence (all types) in women,"Aggravation of incontinence (alpha-1 blockers), lack of efficacy (oral estrogen)",Avoid in women,"Non-selective peripheral alpha-1 blockers: Moderate
Estrogen: High","Non-selective peripheral alpha-1 blockers: Strong
Estrogen: Strong"
Table 3 (Disease),Kidney/urinary tract,Estrogen,Urinary incontinence (all types) in women,"Aggravation of incontinence (alpha-1 blockers), lack of efficacy (oral estrogen)",Avoid in women,"Non-selective peripheral alpha-1 blockers: Moderate
Estrogen: High","Non-selective peripheral alpha-1 blockers: Strong
Estrogen: Strong"
Table 3 (Disease),Kidney/urinary tract,Dabigatran,�long-term treatment of nonvalvular atrial fibrillation or venous thromboembolism,Increased risk of GI bleeding compared with warfarin (based on head-to-head clinical trials) and of GI bleeding and major bleeding compared with apixaban (based on observational studies and meta-analyses) in older adults when used for long-term treatment of nonvalvular atrial fibrillation or VTE.,"Use caution in selecting dabigatran over other DOACs (e.g., apixaban) for long-term treatment of nonvalvular atrial fibrillation or VTE.",Moderate,Strong
Table 3 (Disease),Kidney/urinary tract,Dabigatran,�long-term treatment of nonvalvular atrial fibrillation or venous thromboembolism,,See also criteria on warfarin and rivaroxaban,Moderate,Strong
Table 6 (Renal),Anti-infective,?Ciprofloxacin,<30,"Increased risk of CNS effects (e.g., seizures, confusion) and tendon rupture.",Dosages used to treat common infections typically require reduction when CrCl <30 mL/min.,Moderate,Strong
Table 6 (Renal),Anti-infective,Nitrofurantoin,<30,"Potential for pulmonary toxicity, hepatoxicity, and peripheral neuropathy, especially with long-term use",Avoid if CrCl <30 mL/ min,Low,Strong
Table 6 (Renal),Anti-infective,Trimethoprimsulfamethoxazole,<30,"Increased risk of worsening of kidney function and hyperkalemia; risk of hyperkalemia especially prominent with concurrent use of an ACE, ARB, or ARNI.","Reduce dosage if CrCl is 15�29 mL/min.
Avoid if CrCl <15 mL/ min.",Moderate,Strong
Table 6 (Renal),Cardiovascular and antithrombotics,Amiloride,<30,Hyperkalemia and hyponatremia,Avoid,Moderate,Strong
Table 6 (Renal),Cardiovascular and antithrombotics,Dabigatran,<31,Lack of evidence for efficacy and safety in individuals with a CrCl <30 mL/min. Label dose for patients with CrCl 15�30 mL/min based on pharmacokinetic data.,"Avoid when CrCl
<30 mL/min; dose adjustment is advised when CrCl >30 mL/min in the presence of drug-drug interactions.",Moderate,Strong
Table 6 (Renal),Cardiovascular and antithrombotics,Dofetilide,<60,QTc prolongation and torsades de pointes,"Reduce dose if CrCl is 20�59 mL/min.
Avoid if CrCl <20 mL/ min.",Moderate,Strong
Table 6 (Renal),Cardiovascular and antithrombotics,Edoxaban,15�50,Lack of evidence of efficacy or safety in patients with CrCl <30 mL/min.,"Reduce dose if CrCl is 15�50 mL/min.
Avoid if CrCl <15 or > 95 mL/min.",Moderate,Strong
Table 6 (Renal),Cardiovascular and antithrombotics,Enoxaparin,<30,Increased risk of bleeding,Reduce dose,Moderate,Strong
Table 6 (Renal),Cardiovascular and antithrombotics,Fondaparinux,<30,Increased risk of bleeding,Avoid,Moderate,Strong
Table 6 (Renal),Cardiovascular and antithrombotics,Rivaroxaban,<30,Lack of efficacy or safety evidence in people with CrCl <15 mL/min; limited evidence for CrCl 15�30 mL/min.,"Avoid if CrCl <15 mL/ min.
Reduce the dose if CrCl is 15�50 mL/min following manufacturer dosing recommendations based on indication-specific dosing",Moderate,Strong
Table 6 (Renal),Cardiovascular and antithrombotics,Spironolactone,<30,Hyperkalemia,Avoid,Moderate,Strong
Table 6 (Renal),Cardiovascular and antithrombotics,?Triamterene,<30,Hyperkalemia and hyponatremia,Avoid,Moderate,Strong
Table 6 (Renal),Central nervous system and analgesics,Baclofen,eGFR <60,Increased risk of encephalopathy requiring hospitalization in older adults with eGFR <60 mL/min or who require chronic dialysis.,"Avoid baclofen in older adults with impaired kidney function (eGFR <60 mL/min). When baclofen cannot be avoided, use the lowest effective dose and monitor for signs of CNS toxicity, including altered mental status.",Moderate,Strong
Table 6 (Renal),Central nervous system and analgesics,Duloxetine,<30,"Increased GI adverse effects (nausea, diarrhea)",Avoid,Moderate,Weak
Table 6 (Renal),Central nervous system and analgesics,Gabapentin,<60,CNS adverse effects,Reduce dose,Moderate,Strong
Table 6 (Renal),Central nervous system and analgesics,Levetiracetam,?80,CNS adverse effects,Reduce dose,Moderate,Strong
Table 6 (Renal),Central nervous system and analgesics,Pregabalin,< 30,CNS adverse effects,Reduce dose,Moderate,Strong
Table 6 (Renal),Central nervous system and analgesics,Tramadol,<60,CNS adverse effects,Immediate release: reduce dose Extended-release: avoid,Low,Weak
Table 6 (Renal),Gastrointestinal,Cimetidine,<30,Mental status changes,Reduce dose,Moderate,Strong
Table 6 (Renal),Gastrointestinal,Famotidine,<50,Mental status changes,Reduce dose,Moderate,Strong
Table 6 (Renal),Gastrointestinal,Nizatidine,<50,Mental status changes,Reduce dose,Moderate,Strong
Table 6 (Renal),Hyperuricemia,Colchicine,<30,"GI, neuromuscular, and bone marrow toxicity",Reduce dose; monitor for adverse effects.,Moderate,Strong
Table 6 (Renal),Hyperuricemia,Probenecid,<30,Loss of effectiveness,Avoid,Moderate,Strong
